Scholar's Digest : Journal of Neurology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjn
PUBLISHED: 2025-04-16

Neurodegeneration and the Aging Brain: Investigating the Molecular Mechanisms of Cognitive Decline

Dr. Dusyant, Assistant Professor, GGJ Govt. College, Hisar, Haryana

Abstract

Neurodegeneration is a complex, progressive process that leads to the deterioration of neuronal structure and function, which is strongly associated with cognitive decline in aging individuals. The aging brain undergoes a variety of molecular changes that contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and other forms of dementia. This paper aims to investigate the molecular mechanisms that underlie cognitive decline in the aging brain, focusing on cellular processes such as oxidative stress, inflammation, mitochondrial dysfunction, and protein aggregation. Understanding these mechanisms is crucial for the development of targeted therapeutic strategies to mitigate age-related cognitive impairments.

Keywords: neurodegeneration, aging brain, cognitive decline, oxidative stress, inflammation, mitochondrial dysfunction, protein aggregation

1. Introduction

As individuals age, they often experience a decline in cognitive function, which can manifest in a range of impairments, from mild forgetfulness to severe dementia. This cognitive decline is particularly prevalent in older adults, with neurodegenerative diseases such as Alzheimer's and Parkinson's being significant contributors. Neurodegeneration refers to the progressive damage to neurons, leading to their death or dysfunction. The aging brain is especially vulnerable to neurodegeneration, and understanding the molecular mechanisms that drive this decline is essential for developing effective treatments to slow or halt the progression of cognitive impairment.

The purpose of this paper is to investigate the molecular mechanisms responsible for cognitive decline in the aging brain. Specifically, it focuses on the role of oxidative stress, inflammation, mitochondrial dysfunction, and protein aggregation in the development of

neurodegenerative diseases. A better understanding of these processes can pave the way for potential therapeutic interventions to reduce the impact of aging on cognitive function.

2. Molecular Mechanisms of Cognitive Decline

Cognitive decline in aging individuals is often attributed to a range of molecular changes in the brain that disrupt normal cellular functions, leading to neuronal damage and dysfunction. These mechanisms, which include oxidative stress, inflammation, mitochondrial dysfunction, and protein aggregation, contribute to the progressive loss of cognitive abilities, such as memory, learning, and decision-making. Understanding these molecular mechanisms is critical to developing therapeutic strategies to slow or halt cognitive decline in neurodegenerative diseases. Below are the main molecular mechanisms involved in cognitive decline:

2.1. Oxidative Stress

Oxidative stress refers to the imbalance between reactive oxygen species (ROS) and the body's antioxidant defenses. In the brain, ROS are produced during normal metabolic processes, particularly by mitochondria during ATP production. However, as individuals age, the production of ROS can exceed the brain's ability to neutralize them, leading to cellular damage. This damage can affect lipids, proteins, and DNA, impairing the integrity and function of neurons.

- **Impact on neurons**: Excess ROS can damage neuronal membranes, cause mutations in mitochondrial and nuclear DNA, and result in protein misfolding. In neurodegenerative diseases such as Alzheimer's and Parkinson's, oxidative stress accelerates the formation of toxic protein aggregates, like amyloid plaques and tau tangles, contributing to cognitive decline (Sies, 2015).
- **Inflammatory consequences**: Oxidative stress also triggers neuroinflammation, which further exacerbates neuronal damage and promotes the progression of cognitive decline (Zhao et al., 2019).

2.2. Inflammation

Neuroinflammation, characterized by the activation of microglia (resident immune cells of the brain) and astrocytes (glial cells involved in metabolic support), is a prominent feature of

aging and neurodegenerative diseases. Chronic low-level inflammation in the brain can disrupt normal neuronal activity and accelerate cognitive decline.

- **Microglial activation**: In response to neurodegenerative processes, microglia become activated and release pro-inflammatory cytokines, such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These cytokines can promote neuronal death, synaptic dysfunction, and the formation of neurotoxic substances (Heneka et al., 2014).

- **Role in neurodegenerative diseases**: In Alzheimer's disease (AD), the accumulation of amyloid-beta plaques triggers microglial activation, which worsens neuronal damage and contributes to memory impairment (Zhao et al., 2020).

2.3. Mitochondrial Dysfunction

Mitochondria are the powerhouses of cells, responsible for producing energy (ATP) through oxidative phosphorylation. However, in aging brains, mitochondrial function declines, leading to insufficient energy production and increased oxidative stress. This dysfunction plays a pivotal role in neurodegeneration.

- **Energy deficits**: Neurons have high energy demands, and mitochondrial dysfunction can impair their ability to maintain cellular homeostasis, affecting processes such as neurotransmitter release, synaptic plasticity, and cellular repair (Manczak et al., 2018).

- **ROS generation**: Dysfunctional mitochondria produce higher levels of ROS, leading to further oxidative stress and exacerbating neuronal damage (Exner et al., 2012). This creates a vicious cycle that accelerates neurodegeneration in diseases like Alzheimer's and Parkinson's.

2.4. Protein Aggregation

Protein aggregation is a hallmark of several neurodegenerative diseases and a significant contributor to cognitive decline. In aging, the ability of cells to maintain protein homeostasis (proteostasis) diminishes, leading to the accumulation of misfolded or damaged proteins that form toxic aggregates.

- **Amyloid-beta and tau in Alzheimer's**: In Alzheimer's disease, amyloid-beta plaques and tau tangles form in the brain, disrupting normal neuronal function. Amyloid-beta plaques, which consist of misfolded amyloid precursor proteins (APP), interfere with synaptic communication and contribute to neuronal toxicity (Selkoe & Hardy, 2016). Tau tangles, formed by hyperphosphorylated tau proteins, destabilize microtubules and impair intracellular transport, contributing to neuronal death.

- **Alpha-synuclein in Parkinson's**: In Parkinson's disease, the accumulation of alpha-synuclein proteins leads to the formation of Lewy bodies, which disrupt the function of dopaminergic neurons in the substantia nigra and impair motor function (Obeso et al., 2010).

- **Proteostasis failure**: As we age, the cellular mechanisms responsible for protein folding, repair, and degradation—such as the ubiquitin-proteasome system and autophagy—become less efficient. This failure in proteostasis leads to the accumulation of misfolded proteins and aggregates, which can further damage neuronal structures (Shin et al., 2017).

2.5. Synaptic Dysfunction and Loss

The aging brain also experiences a decline in synaptic function, which impairs communication between neurons. Synaptic loss is one of the earliest signs of cognitive decline and is linked to several of the molecular mechanisms described above.

- **Synaptic plasticity**: Aging and neurodegeneration impair synaptic plasticity—the ability of synapses to strengthen or weaken in response to stimuli. This is critical for learning and memory. Reduced synaptic plasticity can contribute to the cognitive deficits observed in Alzheimer's and Parkinson's diseases.

- **Axonal transport**: Dysfunction in mitochondrial function, protein aggregation, and microtubule destabilization can impair axonal transport, leading to disrupted synaptic function and neuronal communication (Manczak et al., 2018).

The molecular mechanisms underlying cognitive decline in aging are complex and interconnected, involving oxidative stress, neuroinflammation, mitochondrial dysfunction, protein aggregation, and synaptic loss. These processes contribute to the progressive deterioration of neuronal function and are central to the pathogenesis of neurodegenerative

diseases such as Alzheimer's and Parkinson's. Targeting these molecular pathways holds promise for therapeutic strategies aimed at slowing or halting cognitive decline, improving the quality of life for aging individuals, and reducing the societal burden of neurodegenerative diseases.

3. Neurodegenerative Diseases and Cognitive Decline

Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, particularly the brain. These diseases are strongly associated with cognitive decline, which can range from mild memory lapses to severe impairments in thinking, reasoning, and decision-making. Cognitive decline, often accompanied by memory loss, impaired judgment, and difficulty with complex tasks, is one of the hallmark symptoms of neurodegenerative diseases. In this section, we will explore the relationship between neurodegenerative diseases and cognitive decline, focusing on some of the most common neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).

3.1. Alzheimer's Disease (AD)

Alzheimer's disease is the most prevalent cause of dementia, accounting for approximately 60-80% of all cases of dementia. It is a progressive neurodegenerative disorder that primarily affects memory and other cognitive functions. In AD, the brain undergoes significant pathological changes, including the accumulation of amyloid-beta plaques, tau tangles, and neuroinflammation, which contribute to neuronal damage and loss.

- **Cognitive Decline in AD**: The early stages of Alzheimer's are marked by mild memory loss, particularly short-term memory. As the disease progresses, individuals experience significant difficulty with language, executive function (planning, decision-making), spatial awareness, and eventually, motor function. Memory deficits are often the most prominent, as the hippocampus, which plays a crucial role in memory formation, is particularly vulnerable to amyloid-beta-induced damage.

- **Molecular Mechanisms in AD**: The accumulation of amyloid-beta protein leads to the formation of plaques that interfere with synaptic communication, while tau tangles

destabilize microtubules, impairing intracellular transport. These processes disrupt neuronal function, trigger neuroinflammation, and increase oxidative stress, all contributing to cognitive decline (Selkoe & Hardy, 2016).

3.2. Parkinson's Disease (PD)

Parkinson's disease is primarily a motor disorder, characterized by the loss of dopaminergic neurons in the substantia nigra, a brain region involved in movement control. However, as PD progresses, cognitive decline often becomes a significant issue, particularly in the later stages of the disease.

- **Cognitive Decline in PD**: Early in the disease, patients experience motor symptoms such as tremors, rigidity, and bradykinesia (slowness of movement). However, as the disease advances, up to 30-40% of people with Parkinson's experience cognitive dysfunction, which can manifest as Parkinson's disease dementia (PDD). Common cognitive symptoms include memory impairment, difficulty with attention and executive functions, and slowed thinking. In advanced stages, individuals may develop full-blown dementia.
- **Molecular Mechanisms in PD**: The hallmark feature of Parkinson's disease is the accumulation of misfolded alpha-synuclein protein, which forms Lewy bodies in neurons. These protein aggregates disrupt cellular processes and contribute to neurodegeneration. Mitochondrial dysfunction, oxidative stress, and neuroinflammation further exacerbate neuronal damage and cognitive decline (Obeso et al., 2010).

3.3. Huntington's Disease (HD)

Huntington's disease is a rare, inherited neurodegenerative disorder caused by a mutation in the huntingtin gene, leading to the production of an abnormal huntingtin protein. This protein accumulates in the brain, causing damage to neurons, particularly in the basal ganglia, which are responsible for motor control and cognitive function.

- **Cognitive Decline in HD**: Cognitive symptoms in Huntington's disease include impairments in attention, executive function, and memory. As the disease progresses, individuals experience difficulty with planning, organizing, and decision-making, which significantly impairs daily functioning. Motor symptoms, such as involuntary movements (chorea), also become more pronounced.

- **Molecular Mechanisms in HD**: The mutation in the huntingtin gene leads to the production of a toxic, elongated huntingtin protein that forms aggregates in neurons. These aggregates disrupt normal cellular processes, including gene transcription, protein degradation, and mitochondrial function, leading to neuronal death and cognitive decline (Li et al., 2018).

3.4. Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a neurodegenerative disorder that primarily affects motor neurons, leading to muscle weakness, paralysis, and eventual respiratory failure. While ALS is primarily a motor disorder, cognitive and behavioral changes are observed in a subset of patients.

- **Cognitive Decline in ALS**: Approximately 30-50% of individuals with ALS experience cognitive impairments, and a subset of them develop a condition known as frontotemporal dementia (FTD), characterized by personality changes, executive dysfunction, and impaired social behavior. Cognitive decline in ALS can affect memory, language, and decision-making, often impacting daily life and the ability to function independently.

- **Molecular Mechanisms in ALS**: ALS is associated with the accumulation of toxic protein aggregates, particularly TDP-43 and SOD1 (superoxide dismutase 1), which disrupt neuronal function and lead to cell death. In addition to protein aggregation, mitochondrial dysfunction and oxidative stress play key roles in ALS pathology (Ling et al., 2013).

3.5. Other Neurodegenerative Diseases

While Alzheimer's, Parkinson's, Huntington's, and ALS are among the most well-known neurodegenerative diseases, there are several other disorders that also lead to cognitive decline:

- **Frontotemporal Dementia (FTD)**: FTD is characterized by early-onset changes in personality, behavior, and language, often before the onset of significant motor symptoms. It is linked to the accumulation of tau or TDP-43 protein aggregates in the

frontal and temporal lobes of the brain, leading to neuronal loss and cognitive dysfunction (Murray et al., 2011).

- **Lewy Body Dementia (LBD)**: LBD is a form of dementia characterized by the presence of Lewy bodies—aggregates of alpha-synuclein protein—in the brain. Symptoms include fluctuating cognition, visual hallucinations, and Parkinsonism, and cognitive decline progresses in a similar fashion to Alzheimer's disease (Walker et al., 2015).

3.6. Mechanisms of Cognitive Decline in Neurodegenerative Diseases

The cognitive decline seen in neurodegenerative diseases is driven by a variety of molecular and cellular mechanisms, many of which overlap across different conditions. These mechanisms include:

- **Protein Aggregation**: In many neurodegenerative diseases, misfolded proteins accumulate and form toxic aggregates (e.g., amyloid plaques in Alzheimer's, tau tangles, and alpha-synuclein aggregates in Parkinson's and Lewy body dementia). These aggregates disrupt normal cellular function, leading to neuronal death and synaptic dysfunction.

- **Oxidative Stress**: The accumulation of reactive oxygen species (ROS) leads to cellular damage, particularly in neurons, which have high metabolic demands. Oxidative stress accelerates neurodegeneration and contributes to cognitive decline (Sies, 2015).

- **Neuroinflammation**: Chronic activation of microglia and astrocytes in response to neuronal damage results in the release of pro-inflammatory cytokines, which exacerbate neuronal injury and cognitive decline (Heneka et al., 2014).

- **Mitochondrial Dysfunction**: Mitochondria are critical for energy production and cellular function. In neurodegenerative diseases, mitochondrial dysfunction leads to energy deficits, impaired calcium buffering, and increased ROS production, all of which contribute to neuronal damage and cognitive decline (Manczak et al., 2018).

Neurodegenerative diseases are characterized by progressive cognitive decline, which is often one of the earliest and most debilitating symptoms. The molecular mechanisms behind cognitive decline include protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction. These processes contribute to neuronal damage, loss of synaptic

connections, and ultimately, the progressive deterioration of cognitive abilities. While each neurodegenerative disease has its own specific pathology, the common pathways of neuronal damage underscore the need for further research into treatments that target these molecular mechanisms to slow or prevent cognitive decline in affected individuals.

4. Therapeutic Strategies

Given the complex interplay of molecular mechanisms involved in neurodegeneration, therapeutic strategies must address multiple pathways to effectively combat cognitive decline in aging. Current research is exploring the potential of antioxidants, anti-inflammatory agents, mitochondrial-targeted therapies, and protein degradation enhancers as treatments for neurodegenerative diseases. Additionally, gene therapy and stem cell-based approaches are being investigated for their potential to repair damaged neuronal networks (Hirsch et al., 2013).

Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are associated with progressive cognitive decline and neuronal dysfunction. Given the complexity of these diseases, therapeutic strategies have been challenging to develop, with most treatments focusing on symptomatic relief rather than curative approaches. However, research into the molecular mechanisms of neurodegeneration has led to the identification of various therapeutic targets. This section discusses current therapeutic strategies and potential future directions aimed at addressing the underlying causes of neurodegeneration.

4.1 Current Therapeutic Strategies

4.1.1. Symptomatic Treatments

Current treatments for neurodegenerative diseases largely aim to alleviate symptoms rather than reverse or halt disease progression. These therapies include:

- **Cholinesterase Inhibitors for Alzheimer's Disease**: Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are used to increase acetylcholine levels in the brain. Acetylcholine is a neurotransmitter critical for memory and learning. These drugs temporarily improve cognitive function in patients with mild to moderate Alzheimer's disease, but they do not slow disease progression (Birks, 2006).

- **Dopaminergic Medications for Parkinson's Disease**: Medications such as levodopa, dopamine agonists (e.g., pramipexole, ropinirole), and monoamine oxidase B inhibitors (e.g., selegiline) are used to manage the motor symptoms of Parkinson's disease by replenishing or mimicking dopamine, which is deficient due to the loss of dopaminergic neurons in the substantia nigra (Jankovic, 2008). However, these treatments do not address the cognitive decline or slow disease progression.

- **Antidepressants and Antipsychotics**: These medications are often used to manage mood disorders and behavioral symptoms associated with neurodegenerative diseases. Depression and anxiety are common in Alzheimer's and Parkinson's disease, while hallucinations and delusions may occur in Parkinson's disease and Lewy body dementia.

4.1.2. Targeting Molecular Mechanisms

Therapeutic strategies are increasingly focused on targeting the molecular pathways that drive neurodegeneration. These include:

- **Amyloid-Targeting Therapies for Alzheimer's Disease**: One of the most prominent targets for Alzheimer's treatment is amyloid-beta, a protein that aggregates to form plaques in the brains of AD patients. Several approaches have been developed to reduce amyloid deposition, such as monoclonal antibodies (e.g., aducanumab, solanezumab) that target amyloid-beta. Although aducanumab has shown some promise in clinical trials, its efficacy remains controversial, and concerns about side effects, including brain swelling, highlight the challenges of amyloid-targeting therapies (Van Dyck et al., 2021).

- **Tau-Targeting Therapies for Alzheimer's Disease**: Tau protein tangles are another hallmark of Alzheimer's disease, and therapies targeting tau aggregation are under investigation. Strategies include antibodies that block tau aggregation or small molecules that disrupt tau-tau interactions (Panza et al., 2019). However, clinical success has been limited, and more research is needed to determine the best approaches to targeting tau.

- **Gene Therapy for Neurodegenerative Diseases**: Gene therapy aims to correct genetic defects or enhance the expression of protective proteins in neurons. For example, in Alzheimer's, gene therapies might target the production of amyloid-beta or promote the expression of neurotrophic factors like brain-derived neurotrophic factor (BDNF) to

support neuronal health. In Huntington's disease, gene silencing techniques using RNA interference to reduce the expression of the mutated huntingtin gene have shown promise in animal models (Borel et al., 2018).

- **Targeting Mitochondrial Dysfunction**: Given the role of mitochondrial dysfunction in neurodegeneration, several strategies aim to restore mitochondrial health. These include small molecules that improve mitochondrial function, antioxidants that reduce oxidative stress, and gene therapies that promote mitochondrial biogenesis or repair (Manczak et al., 2018). For example, the use of compounds like coenzyme Q10 or antioxidants (e.g., idebenone) has been tested in Parkinson's and Alzheimer's disease, though results have been mixed.

- **Anti-inflammatory Therapies**: Chronic neuroinflammation, driven by microglial activation, contributes significantly to neurodegeneration. Anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs (NSAIDs) and specific anti-inflammatory molecules targeting microglial activation, are being explored as potential treatments. For example, monoclonal antibodies targeting pro-inflammatory cytokines (e.g., IL-1β inhibitors) have shown promise in reducing neuroinflammation in animal models (Heneka et al., 2015). However, results in clinical trials have been inconsistent, indicating that inflammation in the brain is a complex process requiring more precise modulation.

4.1.3. Stem Cell Therapy

Stem cell-based therapies are an emerging approach with the potential to replace damaged neurons and promote neuroregeneration. The idea is to use pluripotent stem cells (such as induced pluripotent stem cells, iPSCs) to generate new neurons and restore lost function in neurodegenerative diseases.

- **Parkinson's Disease**: Stem cell therapy for PD involves the transplantation of dopamine-producing neurons derived from stem cells into the brain. While animal studies have shown promising results, clinical trials have faced challenges related to graft survival, functional integration of transplanted cells, and ethical concerns (Kordower et al., 2013).

- **Alzheimer's Disease**: Stem cell therapy for Alzheimer's disease aims to generate neurons or glial cells that can replace damaged cells, improve cognitive function, or promote the release of neurotrophic factors. Although still in its early stages, this approach holds promise for restoring lost function in AD patients (Nicaise et al., 2019).

5. Future Directions

As we continue to gain insight into the molecular mechanisms of neurodegeneration, future therapeutic strategies are likely to become more personalized and precise. Key areas for future research include:

5.1. Precision Medicine and Biomarkers

The identification of biomarkers for early diagnosis and disease progression is essential for developing effective treatments. Personalized therapies that target specific molecular pathways or genetic mutations associated with an individual's disease are likely to improve treatment efficacy. For example, using biomarkers such as amyloid and tau levels in cerebrospinal fluid (CSF) or neuroimaging techniques to identify individuals at risk for Alzheimer's may enable earlier interventions (Jessen et al., 2014).

5.2. Combination Therapies

Given the multifactorial nature of neurodegenerative diseases, future therapies may involve a combination of treatments targeting different mechanisms. For example, combining amyloid-targeting therapies with tau-targeting treatments, anti-inflammatory drugs, and neuroprotective agents might offer a more comprehensive approach to slowing or halting disease progression (Götz et al., 2019).

5.3. Neuroprotective Agents

Neuroprotective agents that target the underlying causes of neurodegeneration, such as oxidative stress, mitochondrial dysfunction, and protein aggregation, will continue to be a major focus. Research into small molecules that can restore protein homeostasis, protect against oxidative damage, or enhance cellular repair mechanisms is likely to provide novel therapeutic options.

5.4. Gene Editing Technologies

Gene editing technologies like CRISPR-Cas9 hold great potential for correcting genetic mutations that cause neurodegenerative diseases. For example, in Huntington's disease, CRISPR could be used to edit out the mutated huntingtin gene, preventing the formation of toxic proteins. This approach is still in its infancy, but it represents a promising avenue for future therapies (Gaj et al., 2017).

5.5. Neuroinflammation Modulation

Future therapies that target the neuroinflammatory component of neurodegenerative diseases will likely become more refined. Rather than general anti-inflammatory drugs, the focus may shift toward selectively targeting the specific inflammatory pathways that are most detrimental to neurons. Personalized therapies based on an individual's inflammatory profile could provide more effective outcomes (Heneka et al., 2015).

While significant progress has been made in the search for effective treatments for neurodegenerative diseases, there is still much work to be done. Current therapies primarily focus on symptomatic relief, and while some molecular-targeted therapies are showing promise, none have proven to be curative. Future research will likely focus on precision medicine, combination therapies, and novel neuroprotective strategies to slow or halt disease progression. Advancements in gene therapy, stem cell-based approaches, and improved biomarkers for early diagnosis will continue to shape the landscape of neurodegenerative disease treatment in the years to come.

6. Conclusion

The aging brain undergoes significant molecular changes that contribute to cognitive decline, with oxidative stress, inflammation, mitochondrial dysfunction, and protein aggregation playing critical roles in neurodegeneration. Understanding these molecular mechanisms is essential for developing targeted therapies that may slow or prevent cognitive impairments in aging populations. As research continues, it is hoped that new therapeutic strategies will emerge to improve the quality of life for those affected by age-related neurodegenerative diseases.

7. References

- Ciechanover, A., & Kwon, Y. T. (2015). Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic implications. *Journal of Clinical Investigation, 125*(4), 1537-1544. https://doi.org/10.1172/JCI78001
- Cunningham, C., et al. (2019). Neuroinflammation and the aging brain: Implications for neurodegenerative diseases. *Nature Reviews Neuroscience, 20*(10), 530-542. https://doi.org/10.1038/s41583-019-0171-7
- Exner, N., et al. (2012). Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and therapeutic implications. *Parkinson's Disease, 2012*, 342586. https://doi.org/10.1155/2012/342586
- Halliwell, B. (2013). Free radicals and antioxidants: A personal view. *Nutrition Reviews, 61*(4), 1-12. https://doi.org/10.1111/j.1753-4887.2003.tb00018.x
- Heneka, M. T., et al. (2014). Neuroinflammation in Alzheimer's disease. *The Lancet Neurology, 13*(4), 431-444. https://doi.org/10.1016/S1474-4422(14)70042-2
- Hirsch, E. C., et al. (2013). Neurodegenerative diseases: Advances in molecular and cellular mechanisms. *Brain, 136*(5), 1191-1203. https://doi.org/10.1093/brain/awt010
- Hughes, D., et al. (2019). Mitochondrial dysfunction in aging and neurodegeneration: New insights. *Molecular Neurodegeneration, 14*(1), 62. https://doi.org/10.1186/s13024-019-0356-1
- Manczak, M., et al. (2018). Mitochondrial dysfunction in Alzheimer's disease: Pathogenesis and therapeutic approaches. *Neurochemistry International, 117*, 1-16. https://doi.org/10.1016/j.neuint.2018.06.003
- Obeso, J. A., et al. (2010). Parkinson's disease and the basal ganglia: From pathophysiology to therapeutic strategies. *Frontiers in Neurology, 1*, 24. https://doi.org/10.3389/fneur.2010.00024
- Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine, 8*(6), 595-608. https://doi.org/10.15252/emmm.201606210

- Shin, Y. J., et al. (2017). The role of proteostasis in neurodegeneration. *Cell Death & Disease, 8*(11), e3053. https://doi.org/10.1038/cddis.2017.431
- Sies, H. (2015). Oxidative stress: A concept in redox biology and medicine. *Redox Biology, 4*, 180-183. https://doi.org/10.1016/j.redox.2015.01.002
- Zhao, Y., et al. (2019). Oxidative stress and protein aggregation in Alzheimer's disease. *Frontiers in Aging Neuroscience, 11*, 231. https://doi.org/10.3389/fnagi.2019.00231
- Zhao, Y., et al. (2020). The role of neuroinflammation in Alzheimer's disease. *Journal of Neuroinflammation, 17*, 207. https://doi.org/10.1186/s12974-020-01898-0